AZN Stock Chart & Fundamental Analysis

Interactive Chart

About AstraZeneca PLC

Name

AstraZeneca PLC

CEO

Pascal Claude Roland Soriot

Website

www.astrazeneca.com

Industry

Healthcare

Year Founded

1999

Employees

94,300

AstraZeneca PLC is a biopharmaceutical company that discovers, develops, and supplies medicines used in hospitals and clinics around the world. The operating idea is steady and practical: move research through development, manufacture to consistent standards, and support appropriate use with clear guidance for clinicians. Programs focus on conditions that require long-term treatment and careful monitoring, so labeling, education, and supply planning sit close to scientific work. Country teams adapt access and information to local frameworks while holding to common safety principles. The purpose is to turn complex science into options that fit daily care, with availability that health systems can plan around rather than chase.

Analyst Ratings

Consensus Recommendation

Buy14

Hold7

Sell2

Fundamentals & Financials

Revenue (TTM)

$58.7B

Net Income (TTM)

$10.2B

EPS (TTM)

$13.2

ROA (TTM)

9.09%

Current Ratio

0.94

Dividend Yield

0.097%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q4 2025	Q3 2025	Q2 2025
Revenue	$15,503M	$15,191M	$14,457M
Cost of Sales	$3,118M	$2,801M	$2,473M
Gross Profit	$12,385M	$12,390M	$11,984M
Operating Income	$2,978M	$3,583M	$3,508M
Net Income	$2,326M	$2,533M	$2,450M
EPS	$3.02	$3.26	$3.16

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

AstraZeneca PLC's Technical Indicators Summary

AstraZeneca presents a bullish technical profile with broad confirmation across momentum, MACD and moving averages; price sits comfortably above short-, medium- and long-term averages and OBV shows accumulation. RSI is positive and momentum is constructive while ADX suggests only moderate trend strength, and volatility is muted relative to the move. The pivot is near current levels, adding a nearby reference point. Technical takeaway: bullish — price above major averages with volume and momentum support, albeit without an especially strong trend reading.

Buy

14 signals

Neutral

7 signals

Sell

2 signals

Overall: Bullish61% Bullish signals

Indicator	Value	Signal	Explanation
RSI (14)	61.96	Neutral	RSI (61.96) is neutral.
Stochastic %K (14, 3, 3)	89.90	Sell	Stochastic (89.90) > 80, indicating overbought.
CCI (20)	113.76	Buy	CCI (113.76) > 100, indicating strong upward momentum.
WPR (14)	-13.06	Sell	Williams %R (-13.06) > -20, indicating overbought.
Momentum (10)	20.63	Buy	Momentum (20.63) is positive.
MFI	67.82	Neutral	MFI (67.82) is neutral.
MACD Level (12, 26)	2.61	Buy	Confirmed uptrend: MACD (2.61) is positive and above its signal line (0.86).
Bollinger Bands	$178.23 - $209.29	Neutral	Price is within the bands.
ATR (14)	$4.53 (2.22%)	Neutral	Moderate Volatility (2.22%).
ADX (14)	18.65	Neutral	Weak or consolidating trend (ADX < 25). ADX(18.65), +DI(31.85), -DI(26.60)
OBV	85,427,945	Buy	Bullish volume pressure: OBV is above its 20-day SMA. OBV(85,427,945), 20D-SMA-OBV(79,410,182)
Classic Pivot Point	$204.49	Neutral	Price ($204.03) below pivot ($204.49) but above support S1 ($202.47) — mildly bearish, not confirmed.
Fibonacci Pivot Point	$204.49	Neutral	Price ($204.03) below pivot ($204.49) but above support S1 ($202.76) — mildly bearish, not confirmed.
Simple Moving Averages	$173.26 - $200.07(5 indicators)	Buy	SMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key SMA averages.
Exponential Moving Averages	$173.91 - $200.23(5 indicators)	Buy	EMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key EMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

AZN finished -0.49% below yesterday's close of 204.99. The session closed with a cautious tilt in AZN derivatives, as PCR finished at 1.05. AZN drifts lower as China headwinds weigh, while UBS and Citi maintain Buy on a rich pipeline ahead of quarterly results.

Price Change

from $204.02 close

+$0.06

Trading Volume

Below avg (2.1M)

1.4M

vs S&P 500 Today

Underperforming Market

-0.83%

52-Week Position

Upper range

89.6%